Topics

Companies Related to "Protein Coupled Bile Acid Receptor Protein Coupled Receptor" [Most Relevant Company Matches] RSS

23:38 EST 17th February 2020 | BioPortfolio

Here are the most relevant search results for "Protein Coupled Bile Acid Receptor Protein Coupled Receptor" found in our extensive corporate database of over 50,000 company records.

Showing "Protein Coupled Bile Acid Receptor Protein Coupled Receptor" Companies 1–25 of 1,400+

Extremely Relevant

PanVera Corporation

Protein Kinase C Assays Androgen Receptor, Ligand Binding Domain Estrogen Receptor-Beta 1, Long Form Tau Protein, microtubule-associated protein, histidine-tagged Cytochrome P450 Monoclonal Antibodiesa broad selection of antibodies can be found here.


ConfometRx

ConfometRx is pioneering a platform of structure-based drug development tools that facilitate target validation, lead identification, and lead optimization for G protein coupled receptor (GPCR) targets. This platform includes biochemical and biophysical technologies for defining drug binding sites; the production of pure, functional GPCRs for high-resolution structure determination by crystallogra...

Receptos, Inc.

Receptos is a biopharmaceutical company developing best- and first-in-class G protein-coupled receptor (GPCR) therapeutic candidates through information-driven drug discovery, including GPCR structure determination. The company’s lead program is a best-in-class S1P1 small molecule, agonist candidate for autoimmune indications, including multiple scler...


Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Escient Pharmaceuticals

Escient Pharmaceuticals is a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-...

REMD Biotherapeutics, Inc.

REMD Biotherapeutics is a privately held, clinical-stage biotechnology company focused on creating and developing innovative protein-based therapies to treat metabolic diseases and other serious illnesses. The Company was founded by two former Amgen research scientists and has facilities in Camarillo, California and Beijing China (Cosci-REMD Biotherapeutic...

Escient Pharmaceuticals, Inc.

Escient Pharmaceuticals is a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-...

Novasite Pharmaceuticals, Inc

Novasite is a drug discovery company using structure-function relationships in validated G protein coupled receptor targets to find better GPCR modulating drugs.Novasite began as a majority-owned subsidiary of Applied Molecular Evolution, Inc. (“AME”), which was acquired by Eli Lilly in 2004 for $400M. Novasite is the exclusive licensee of AME molecular evolution technology, which the Company ...

Lundbeck Research USA, Inc.

Now that scientists have mapped the human genome, new opportunities exist for developing drugs that exclusively target specific receptors associated with the symptoms and causes of a disease.Receptor-specific drugs provide a new model in drug discovery that can improve the state-of-the-art treatment for many serious and common disorders. Lundbeck Research USA uses this discovery model to pursue n...

Angstrom Pharmaceuticals Incorporated

Ångstrom Pharmaceuticals, Inc. was formed in 1996 to add a new dimension to drug discovery. It is committed to discovering drugs that block the docking of an extracellular regulatory protein (ligand) to its receptor found on the outside of a cell – when this event is responsible for initiating a disease state. Receptors can be identified that trigger several intractable diseases including cance...

Azevan Pharmaceuticals, Inc.

Azevan Pharmaceuticals, Inc. (Azevan or the Company) is developing novel therapeutics for the treatment of disorders of stress, mood, and behavior. The Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. Azevan’s first series of clinical candidates selectively block the effects...

Ideal Protein

Ideal Protein is a medical weight loss program that was developed 23 years ago by physician Dr. Tran Tien Chanh. Ideal Protein is a medical solution protocol based on validated science for safe yet rapid weight loss. It balances the body’s food intake for efficiently burning fat, and helps to reverse the imbalance in insulin that occur with the typica...

Anchor Therapeutics

Anchor Therapeutics is developing first-in-class pepducin drug candidates, novel molecules that can selectively target G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling. For more information, please visit www.anchortx.com.

Ra Pharmaceuticals

Ra Pharma™ is developing Cyclomimetics™, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma’s peptide-like molecules are highly-stable, synthetic products with chemical structures that offer intrinsic cell permeability. Ra Pharma is leveraging its ability to rapidly...

BeneVia

BeneVia® is a healthy nutritional juice drink fortified with the essential vitamins and minerals and specialized protein & amino acid leucine sources for healthy aging. Clinical research has shown that the proprietary BeneVia® blend of these protein and nutrients is four times more effective than other protein sources for improving muscle function and energy levels for daily activity.

Receptor Biology Incorporated

Receptor Biology Inc. produce cloned receptors for pharmacology studies and drug discovery, products include adenosine, cannabinoid, dopamine, muscarinic, serotonin, opoid, bradykinin, transporter, wild type.

Message Pharmaceuticals Incorporated

MESSAGE PHARMACEUTICALS, INC. is an emerging biotechnology company dedicated to developing novel and proprietary screening assays for discovering new drugs. Currently, most drugs act by binding to specific sequences and structures within a target protein, such as a receptor or enzyme, and altering the protein's activity or function. MESSAGE's technology will allow for the identification of drugs...

Evolutec Group plc

Evolutec discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. Evolutec has progressed its lead therapeutic molecule, rEV131, a novel histamine binding protein, from discovery to completion of initial Phase II clinical trials in allergic conjunctivitis, rhinitis and ocular inflammation. Positive preclinical data has also been generated in asthma ...

Target Discovery, Inc.

Target Discovery discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and management of disease. A growing body of scientific literature shows that protein isoforms correlate more precisely with disease state and patient-specific treatment response than current clinical biomarkers. Most protein isoforms (90%) are made by the body after the protein is produced (post-tra...

ProteoChem, Inc.

ProteoChem manufactures protein crosslinkers, analytical standards, and novel proteomics reagents for protein detection and protein modification that are used in mass spectrometry, drug development, diagnostics, and protein biology.

Raptor Pharmaceutical

Raptor Pharmaceutical Inc. is the culmination of years of experience and research by a consortium of scientists, investors, and creative minds with one common goal, the development of novel protein therapeutics directed at unmet medical needs. Raptor was incorporated in the State of Delaware on September 8, 2005. On January 27, 2006, Raptor purchased intellectual property pertaining to the researc...

Arena Pharmaceuticals®

Arena is a biopharmaceutical company developing a broad pipeline of compounds that act on G protein-coupled receptors, or GPCRs. The company focuses on the discovery, development, and commercialization of drugs in four major therapeutic areas: metabolic, cardiovascular, inflammatory, and central nervous system diseases.

Unum Therapeutics Inc.

Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, which is designed to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in which proprietary, tumor-targeting antibodies are armed to improve their therapeut...

Synaptic Pharmaceutical Corporation

Synaptic Pharmaceutical Corporation is a biotechnology company engaged in the development of a broad platform of enabling technology which it calls "human receptor- targeted drug design technology." The Company is utilizing this technology to discover and clone the genes that code for human receptor subtypes that may be associated with specific disorders. The Company and its collaborative part...


More From BioPortfolio on "Protein Coupled Bile Acid Receptor Protein Coupled Receptor"

Quick Search

Corporate Database Quicklinks